SCHEMBL4746069

SCHEMBL4746069

c1cnc2c(c1)-c1cccc3c1c-2cc1c2ccccc2c(-c2ccc4cnccc4c2)cc31

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 2/20 0.47
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
CYP11B1 P15538 3/20 0.37
PRKCI P41743 1/20 0.37
CYP11B2 P19099 2/20 0.36
CYP17A1 P05093 1/20 0.36
CYP19A1 P11511 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
TNF P01375 1/20 0.35
SRC P12931 2/20 0.35
ABL1 P00519 1/20 0.35
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
INSR P06213 1/20 0.35
RET P07949 1/20 0.35
MET P08581 1/20 0.35
ROS1 P08922 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746073 0.95 TDO2 (0.47) TDO2PIK3CDPIK3CBPIK3CGCYP11B1
SCHEMBL4746386 0.92 ALDH1A1 (0.38) TDO2CYP11B1ABL1CYP1A2MAPK1
SCHEMBL4745816 0.89 HTR2B (0.40) CYP11B1CYP11B2CYP17A1CYP19A1MAPK9
SCHEMBL4746384 0.88 ALDH1A1 (0.37) TDO2PIK3CDPIK3CBPIK3CGCYP11B1
SCHEMBL13320365 0.88 TDO2 (0.53) TDO2PIK3CDPIK3CBPIK3CGCYP11B1
SCHEMBL4746287 0.84 PTPRC (0.39) CYP11B1ABL1MAPK1
SCHEMBL13320360 0.83 TDO2 (0.53) TDO2PIK3CDPIK3CBPIK3CGCYP11B1
SCHEMBL4746298 0.82 PTPRC (0.38) PIK3CDCYP11B1ABL1PRKACAMAPK1
SCHEMBL4746300 0.82 PTPRC (0.38) CYP11B1ABL1MAPK1
SCHEMBL4746199 0.82 TNF (0.47) CYP11B1MAPK10TNFIKBKETBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 TDO2 134/4885PIK3CD 2375/4885PIK3CB 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.